SAN DIEGO, CA--(Marketwired - March 31, 2015) - Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today that its abstract entitled “Development of DiffronC gene silencing technology for silencing of the novel leukemia stem cell target NR2F6" was accepted for presentation at the Cold Spring Harbor Conference on RNA & Oligonucleotide Therapeutics, April 8 - 11, 2015.
The conference will consist of symposia and poster presentations on all scientific topics related to the development of RNA and other oligonucleotide-based therapeutic approaches. DiffronC is an siRNA based therapeutic that targets the leukemia and myelodysplastic syndrome stem cell and is based on IP acquired from the University of Toronto as well as IP developed in house.
“Regen BioPharma is extremely pleased that its Director of Molecular Therapeutics, Dr. Christine Ichim has been selected to make a presentation on DiffronC, a cancer therapy aimed at transformation of cancer stem cells into normal cells as a mechanism for treating cancer,” according to the Company’s Chairman & CEO David Koos.
“This conference is regarded by leaders in the fields of molecular biology and gene silencing as one of the most important scientific events in the gene silencing space,” said Christine Ichim, Director of Molecular Therapeutics for Regen BioPharma Inc. “The Cold Spring Harbor Laboratory (CSHL) is one the most respected research institutes in the world. CSHL is one of the pioneers in the discovery of gene silencing.”
The Company believes this conference presents an excellent opportunity for the Company to gain exposure for its research, foster collaborations and develop relationships with key researchers in the field.
ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Cold Spring Harbor Conference on RNA & Oligonucleotide Therapeutics links:
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
619-702-1404 Phone
619-330-2328 Fax
www.regenbiopharma.com
Help employers find you! Check out all the jobs and post your resume.
